Progression of childhood cancers in Europe

Examining NSCLC responses to durvalumab monotherapy

Expanding access to crizotinib using a biomarker-driven approach

Rova-T: First ‘targeted’ treatment for small cell lung cancer shows promise

Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC

Latest in lung cancer from ECC 2015

Regional lymph node irradiation in early breast cancer

ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review

PD-L2 expression and its relevance to anti-PD-1 therapy in cancer

Economics of radiotherapy and radiotherapy boost for high grade invasive breast cancer

EORTC ‘boost no-boost’ trial 20-year follow up: Impact of pathological factors on long-term local control

Melanoma immunotherapy latest and TVEC plus pembrolizumab